MSAM
NTLA icon

Moloney Securities Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Moloney Securities Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,296
Closed -$306K – 287
2017
Q3 		$306K Buy
+12,296
New +$232K 0.14% 187

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Moloney Securities Asset Management's NTLA Position: Q4 2017 in Review

Moloney Securities Asset Management sold out of Intellia Therapeutics (NTLA) in Q4 2017, closing a stake of 12,296 shares — an estimated $306K sold.

Moloney Securities Asset Management first reported a position in NTLA in Q3 2017 and held it in 1 quarter. The position peaked at $306K in Q3 2017. 112 funds tracked by Wall St. Rank hold NTLA as of Q4 2017.

  • Moloney Securities Asset Management reported no remaining Intellia Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Moloney Securities Asset Management sold 12,296 Intellia Therapeutics shares in Q4 2017, an estimated $306K.
  • Moloney Securities Asset Management first reported a position in Intellia Therapeutics in Q3 2017 and held it in 1 quarter.
  • Moloney Securities Asset Management's Intellia Therapeutics position peaked at $306K in Q3 2017.
  • 112 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2017.

Based on Moloney Securities Asset Management's 13F filing for Q4 2017, filed 25 Jan 2018.